Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260073 · ClinicalTrials.gov registry record
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
A clinical trial, sponsored by Almirall, S.A..
- Completed
- Registry status
- 300
- Enrollment target
NCT05260073 is a clinical trial that has completed, run by Almirall, S.A.. The registered enrollment target is 300 participants.
The verdict
NCT05260073 has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
Interventions
- DRUG Tirbanibulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2023-03-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05260073
The ClinicalTrials.gov registry entry for NCT05260073 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tirbanibulin is the first listed.
NCT05260073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05260073 about?
NCT05260073 is a clinical study titled "Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis". The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
What is the current status of trial NCT05260073?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2022-03-09. Estimated completion is 2023-03-07.
What interventions are being tested in trial NCT05260073?
The interventions under investigation include: Tirbanibulin (DRUG).
Who is sponsoring clinical trial NCT05260073?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.